Project Grant R43EY036695
Award Date 8/1/25
Completion Date 7/31/26
Dollars Obligated $358K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Eye Institute (NEI), part of the National Institutes of Health, awarded a $331,131 Project Grant under the Vision Research program (CFDA 93.867) to Physical Sciences Inc. (PSI) to develop and validate a high-resolution retinal imaging system with light flicker capabilities. This system aims to enable objective characterization of the photoreceptor response to light and quantify differences between normal and diseased eyes, particularly for patients with diabetic retinopathy. PSI,...
- The National Eye Institute (NEI) awarded a $312,239 Project Grant under the Vision Research federal grant program (CFDA 93.867) to Shift Pharmaceuticals Holdings, Inc. for the development of an antisense oligonucleotide (ASO) therapeutic to inhibit retinoic acid signaling and mitigate vision loss in retinitis pigmentosa and age-related macular degeneration. The project aims to create a targeted ASO therapy that can block the production of retinoic acid receptors at the cellular level within...
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $144,200 Project Grant to Pennsylvania State University's Milton S. Hershey Medical Center. The grant, effective June 1, 2025 through November 30, 2027, will fund research to characterize the molecular mechanisms underlying increased levels of the protein REDD1 in the retina due to diabetes, and explore alternative intervention strategies for preventing retinal complications caused by...
- This Project Grant award from the National Eye Institute (NEI), part of the U.S. Department of Health and Human Services, aims to advance understanding of the molecular and cellular mechanisms underlying diabetic retinopathy (DR) and diabetic macular edema (DME). The $1,786,652 award, granted on September 15, 2025, supports the application of the "TEMPO" proteomic platform to identify protein biomarker signatures and key cellular drivers of DR stages and DME using human liquid biopsy...
- This $305,321 Project Grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports the clinical development and commercialization of a topical ophthalmic treatment for neovascular age-related macular degeneration (NAMD). The funding will enable the awardee, Neovascularx, Inc., to advance their AMD101 (rifampicin) compound, which aims to provide a less invasive, home-based alternative to the current standard of care intravitreous injections for...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $321,904 Project Grant to Proteris Biotech, Inc. through the Vision Research federal grant program (CFDA 93.867). The award, spanning August 1, 2025 to July 31, 2026, will fund the early development of the natural tear protein clusterin (CLU) as a novel approach to treat dry eye disease. The research aims to conduct non-GMP stability analysis of the drug substance and product, as well as perform...
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $595,302 project grant to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, for the period of April 1, 2025 to March 31, 2030. The project aims to investigate how glucose and lactate support photoreceptor health and function in order to develop new treatment strategies to prevent vision loss. Specifically, the researchers will determine whether the retinal...
- This $348,800 Project Grant was awarded on September 30, 2025 by the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), to N'Waii Inc. in Chicago, Illinois. The grant supports the development of a first-in-class mitochondrially targeted antioxidant drug candidate for the treatment of dry eye disease (DED), a condition affecting 20% of the global adult population. The drug candidate exhibits potent free radical scavenging capabilities and has demonstrated...
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $300,016 project grant to Fannin Partners LLC, a Houston-based biomedical research company, to develop SCG3 raptamers as a novel targeted therapy for wet age-related macular degeneration (AMD). Wet AMD is a leading cause of vision loss, affecting over 1.25 million individuals in the United States. The project aims to create an aptamer-based treatment that targets secretogranin III (SCG3), a...
- This Project Grant award for $679,159 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research on in vivo epigenetic reprogramming of retinal ganglion cells (RGCs) in aging mice with glaucoma. The research aims to identify new therapeutic targets for glaucoma that can protect and rejuvenate RGCs, which are specifically targeted and damaged in this disease leading to vision loss. The 4-year project, awarded to The Schepens Eye...